PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates
- PDF File: images/files//2022/20170619_pm_hdp_takeda_adc-collaboration_engl_final.pdf
- Datum: Monday, 19 June 2017 12:27
- Created on .
- Last updated on .
- Hits: 1766